Drug Trial Radar · NCT03457532
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Dec 16, 2017
Primary completion
Sep 22, 2023
Study completion Sep 22, 2023
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
Conditions
- Advanced Solid Tumor
Interventions
Gumarontinib TabletsDrug
25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT(Dose limit toxity)Time frame: 35 days
- MTD(Max tolerance does)Time frame: 35 days
- BED(Biological effective dose)Time frame: 35 days
- objective response rate (ORR)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.